Improving Reliability of Immunological Assays by Defining Minimal Criteria for Cell Fitness
Authors:
- Rosa V. GarciaRGRosa V. Garcia
- Rita KohenRKRita Kohen
- John D. RiouxJRJohn D. Rioux
- Megan K. LevingsMLMegan K. Levings
- iGenoMed ConsortiumICiGenoMed Consortium
Open Access
- 1 September 2024
- journal article
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 8 (9) , 622-634
Abstract
Human PBMC-based assays are often used as biomarkers for the diagnosis and prognosis of disease, as well as for the prediction and tracking of response to biological therapeutics. However, the development and use of PBMC-based biomarker assays is often limited by poor reproducibility. Complex immunological assays can be further complicated by variation in cell handling before analysis, especially when using cryopreserved cells. Variation in postthaw viability is further increased if PBMC isolation and cryopreservation are done more than a few hours after collection. There is currently a lack of evidence-based standards for the minimal PBMC viability or “fitness” required to ensure the integrity and reproducibility of immune cell–based assays. In this study, we use an “induced fail” approach to examine the effect of thawed human PBMC fitness on four flow cytometry–based assays. We found that cell permeability-based viability stains at the time of thawing did not accurately quantify cell fitness, whereas a combined measurement of metabolic activity and early apoptosis markers did. Investigation of the impact of different types and levels of damage on PBMC-based assays revealed that only when cells were >60–70% live and apoptosis negative did biomarker values cease to be determined by cell fitness rather than the inherent biology of the cells. These data show that, to reproducibly measure immunological biomarkers using cryopreserved PBMCs, minimal acceptable standards for cell fitness should be incorporated into the assay protocol.Keywords
This publication has 65 references indexed in Scilit:
- Bicentric evaluation of stabilizing sampling tubes for assessment of monocyte HLA‐DR expression in clinical samplesCytometry Part B: Clinical Cytometry, 2021
- Biomarker-guided stratification of autoimmune patients for biologic therapyCurrent Opinion in Immunology, 2017
- Standardized whole blood stimulation improves immunomonitoring of induced immune responses in multi-center studyClinical Immunology, 2017
- A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)Cytometry Part A, 2013
- Harmonization of the intracellular cytokine staining assayCancer Immunology, Immunotherapy, 2012
- Apoptosis and Beyond: Cytometry in Studies of Programmed Cell Death2011
- Standardization and optimization of multiparameter intracellular cytokine stainingCytometry Part A, 2008
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and diseaseEuropean Journal of Immunology, 2000
- Reduction of interlaboratory variability in flow cytometric immunophenotyping by standardization of instrument set-up and calibration, and standard list mode data analysisCytometry, 1997